Just as 2006 and 2007 saw an increase options for delivery systems of medications for ADHD, the next generation of medications for ADHD may be just around the corner in 2008 and 2009. These NextGen medications are known as ProDrugs, and they have the potential to change the way medications are prescribed to individuals with ADHD.

Since there has been a recent explosion of new ADHD drugs such as Strattera, or new delivery systems such as Daytrana, or "old drugs in new dresses" such as Concerta, why in the world is it necessary to develop any more new drugs for ADHD? Why should we care?

To the extent that new drugs are just "old drugs in new dresses" for a pharmaceutical company to make money, we don't care. But to the extent that this NextGen of ProDrugs might actually make a difference in people's lives, we are very interested in learning more.

And given that between 30% and 40% of patients cannot tolerate the side-effects of current stimulant medications, and given that today's ADHD medications range from about 60% effective (Strattera) to 80% effective (Ritalin), there is a lot of room for improvement in this field. This is why we like Attend, which is not a drug, but is about 70% effective and with few or no side-effects. It is just not well known.

By developing this next generation of drugs, pharmaceutical companies are betting huge sums of monies that they can develop ADHD drugs that are more efficient for a given individual, and with fewer side-effects. Since there are different types of ADHD, different types of drugs, or drugs that will work on different parts or systems of the brain, will be more efficient than just broad acting CNS stimulants.

Attend is an excellent alternative treatment for ADHD , and is the most advanced "natural alternative ADHD remedy" available today.

It is a powerful, all-natural treatment choice that is Clinically Tested with computerized testing, in addition to parent reports. Attend is one of the most popular alternative choices to ADHD medications such as Ritalin, Strattera, Concerta, Dexedrine, Adderall, or other medications for Attention Deficit Hyperactivity Disorder. As some evidence mounts that stimulants may not be as safe as once thought, many parents are looking for an alternative that works.

Try Attend first!

In 1996 VAXA's Neuro-Scientists developed Attend using cutting edge research with amino acid combinations, Essential Fatty Acids and Lipid complexes, homeopathic medicines, and precursors to specific neurotransmitters.

This combination of neural building materials gives the brain what it needs to optimize performance in filtering out noise from the "outside world," and noise from "the inside world," to focus better on the task at hand. Attend helps children and adults who have problems with attention, learning, or impulse control!

Our guest author is Shane Wong. Mr. Wong is the Editor-in-Chief for Juxtaposition Global Health Magazine, a student-run publication based at the University of Toronto. According to the author: "This article will explore how ADHD medication can empower diagnosed patients, and why fears towards such drugs and the pharmaceutical industry persist across North America."By Guest Author: Christine McGogy

"Ritalin, Ritalin, seizure drugs, Ritalin." Such is the lunchtime rhyme for a typical school nurse in the U.S. as she trots from class to class, dispensing pills into outstretched hands of young children (01/18/99 - New York Times).

Welcome to the uniquely North American psychotropic environment. A continent featuring a prescription drug market for attention-deficit hyperactivity disorder (ADHD) worth over 2-billionUS annually, and where the number of prescriptions have grown four-fold in 20 years and over 90% of prescriptions worldwide originate.

But when patients as young as two-years-old are prescribed drugs that a government puts in the same category as morphine and cocaine, controversy concerning the use of drug treatment for ADHD is bound to arise. This article will explore how ADHD medication can empower diagnosed patients, and why fears towards such drugs and the pharmaceutical industry persist across North America.